Publications

Filter Publications By:

Binimetinib and Encorafenib

03/21/2018

The Lancet Oncology

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

R. Dummer, M.D., et al.

Binimetinib and Encorafenib

01/20/2018

2018 Gastrointestinal Cancers Symposium (ASCO GI)

BEACON CRC Study Safety Lead-in (SLI) in Patients With BRAFV600E Metastatic Colorectal Cancer (mCRC): Efficacy and Tumor Markers

Van Cutsem, et al.

Binimetinib / Cancer

01/20/2018

2018 Gastrointestinal Cancers Symposium (ASCO GI)

Phase 1b/2 Study of Binimetinib in Combination With Nivolumab (NIVO) or NIVO Plus Ipilimumab in Patients With Previously Treated Microsatellite-Stable Metastatic Colorectal Cancer With RAS Mutation

Bendell, et al.

ARRY-382 / CSF1R

11/10/2017

Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

A phase 1b/2 dose-escalation study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF-1R) in combination with pembrolizumab for the treatment of patients with advanced solid tumors

Wael A. Harb, et al.

Binimetinib / Cancer

09/10/2017

European Society for Medical Oncology Congress

Quality of Life in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib Plus Binimetinib vs Vemurafenib or Encorafenib Monotherapy in BRAF-Mutant Melanoma

Helen J. Gogas, et al.

Binimetinib / Cancer

09/10/2017

European Society for Medical Oncology Congress

Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib Plus Binimetinib vs Vemurafenib or Encorafenib Monotherapy in BRAF-Mutant Melanoma

Ana Arance, et al.

Binimetinib and Encorafenib

09/09/2017

European Society for Medical Oncology Congress

RESULTS OF COLUMBUS PART 2: A Phase 3 Trial of Encorafenib Plus Binimetinib Versus Encorafenib in BRAF-Mutant Melanoma

R. Dummer, et al.

Binimetinib / Cancer

09/09/2017

BEACON CRC: Safety Lead-In (SLI) for the Combination of Binimetinib (BINI), Encorafenib (ENCO), and Cetuximab (CTX) in Patients (Pts) with BRAFV600E Metastatic Colorectal Cancer (mCRC)

Huijberts, et al.

Binimetinib / Cancer

06/03/2017

American Society of Clinical Oncology Meeting

Phase 1b/2 Trial of Ribociclib + Binimetinib in Metastatic NRAS-Mutant Melanoma: Safety, Efficacy, and Recommended Phase 2 Dose

Martin Schuler, et al.

Binimetinib and Encorafenib

11/09/2016

2016 Society for Melanoma Research (SMR) Annual Congress

Results of COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma

Keith T. Flaherty, M.D., et al.